Stelzenberg, Germany

Marc Satadler

This inventor holds 1 USPTO granted patent. Top assignee: Boehringer Mannheim Gmbh. Active years: 1999.


% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 1999

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Marc Satadler

Introduction

Marc Satadler is an accomplished inventor based in Stelzenberg, Germany. He is known for his significant contributions to the field of chemistry, particularly in the development of biologically active compounds. His work has led to the creation of a novel compound that has potential applications in various scientific fields.

Latest Patents

Marc Satadler holds a patent for "Papyracillic acid, method for preparation and its use as synthon." This invention relates to a new biologically active compound, as shown in formula (I), and its biologically active derivatives. The derivatives are produced by the reaction of formula (I) with nucleophiles. This innovative approach has opened new avenues for research and application in medicinal chemistry.

Career Highlights

Satadler is currently employed at Boehringer Mannheim GmbH, a company renowned for its advancements in biotechnology and pharmaceuticals. His role at the company allows him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Throughout his career, Marc has worked alongside notable colleagues such as Rudong Shan and Olov Sterner. These collaborations have enriched his research and have been instrumental in the development of his patented innovations.

Conclusion

Marc Satadler's contributions to the field of chemistry exemplify the impact of innovative thinking in science. His patent for Papyracillic acid showcases his dedication to advancing knowledge and technology in the realm of biologically active compounds.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…